Drug Dev
Zelluna Immunotherapy seeks TCR share of voice
Immunotherapy is currently one of the hottest areas in biotech, so differentiating from the crowd is a major challenge for startups in the space. Zelluna Immunotherapy CEO Miguel Forte explains to Scrip how his company intends to get share of voice in the busy TCR landscape.